IGF-1 LR3 + GH stack

Growth hormone exerts most of its anabolic effect indirectly, by driving hepatic IGF-1 production - but it simultaneously raises IGFBP-3 and the acid-labile subunit, which sequester that IGF-1 and cap free levels. The stack's logic is to bypass that ceiling: GH or a secretagogue supplies the direct lipolytic and metabolic effects, while IGF-1 LR3 provides binding-protein-resistant receptor agonism that the liver cannot regulate. Mechanistically this is coherent. Practically, it is the combination in which every risk of both components compounds - GH's insulin resistance sits alongside IGF-1's insulin-mimetic hypoglycaemia, fluid retention adds up, and if insulin is added on top, as it often is in this context, the margin for error becomes very small. Nobody has ever tested this combination in a controlled human study.

Targets: GH receptor, IGF-1 receptor (IGF1R), PI3K/Akt/mTOR pathway, IGF binding proteins (bypassed)

• · The microgram figures refer to the IGF-1 LR3 component only. The GH side is usually 2-4 IU per day of recombinant GH, or a GHRH-plus-GHRP pairing such as CJC-1295 without DAC at 100 mcg with ipamorelin at 200-300 mcg nightly.
• · Substituting a secretagogue for recombinant GH keeps GH release pulsatile and is cheaper, but produces a smaller GH exposure than exogenous GH.

Work out your exact syringe units →

• very commonFluid retention, puffiness and weight gain— Both components contribute; often mistaken for muscle in the first fortnight.
• commonHypoglycaemia— The defining hazard of this stack. Never dose the IGF-1 component fasted, and always have fast carbohydrate within reach.
• commonCarpal tunnel syndrome— Much more likely with the combination than with either alone.
• commonInsulin resistance and raised fasting glucose— GH is diabetogenic; sustained use can push a susceptible person toward diabetes.
• commonJoint pain and stiffness
• rareIntestinal and organ growth with prolonged high-dose use— The acromegaly-pattern risk that comes from chronically elevating both arms of the axis.
• rarePromotion of undetected neoplasia— Both GH and IGF-1 are permissive for cell growth. Screening before starting is the only meaningful mitigation.

• Any active or suspected malignancy - this is the single most important exclusion for the stack.
• Diabetes or significantly impaired glucose tolerance.
• Active proliferative diabetic retinopathy.
• Concurrent insulin use without glucose meter discipline - the combination of GH, IGF-1 and insulin is behind most serious incidents in this space.
• Pregnancy and breastfeeding.
• Untreated sleep apnoea, which GH-related fluid retention worsens.

• cautioninsulin-analogues — The three-way GH/IGF/insulin combination is the highest-risk protocol in recreational peptide use. Hypoglycaemia here can be rapid and severe.
• redundantmk-677 — Adding an oral secretagogue on top of exogenous GH is redundant and compounds water retention and insulin resistance.
• redundanttesamorelin-visceral-fat — Another way of raising the same axis; stacking adds side effects, not effect.

• · Fasting glucose and HbA1c before starting and every 6-8 weeks - non-negotiable for this stack.
• · Serum IGF-1, aiming to stay within the age-adjusted reference range rather than above it.
• · Blood pressure and any symptoms of carpal tunnel or sleep apnoea.
• · Age-appropriate cancer screening current before starting.
• · A glucose meter on hand, used rather than owned.

Recombinant GH is a prescription drug whose non-medical distribution is a federal offence in the US; IGF-1 LR3 is an unapproved research chemical. Both are prohibited at all times in sport by WADA.

• Reviews of the GH/IGF-1 axis, IGF binding proteins and the hepatic regulation of free IGF-1 (review)
• Clinical literature on growth hormone effects on body composition, glucose tolerance and fluid retention in adults (trial)
• Case reports and reviews of adverse events from non-medical growth hormone and insulin use in bodybuilding (other)

The stated logic of this stack is that GH's anabolic action is largely mediated by hepatic IGF-1, so adding IGF-1 directly means the anabolic signal no longer depends on a liver that may not respond well. That is superficially reasonable and mostly wrong, and understanding why is the point of this record. GH does not act only through hepatic IGF-1. It signals through the GH receptor and JAK2-STAT5 directly in adipose tissue, where it activates hormone-sensitive lipase and adipose triglyceride lipase and inhibits lipoprotein lipase, producing the lipolytic effect that is arguably the main reason people take it. It also induces local IGF-1 expression within skeletal muscle itself, which is autocrine and paracrine and probably more relevant to hypertrophy than the circulating pool. And it raises IGFBP-3 and the acid-labile subunit, which is what creates the ternary complex reservoir that gives circulating IGF-1 its long residence time. So adding LR3 does not fill a gap in GH's mechanism; it adds a second, more crudely delivered IGF-1 signal on top of one the GH is already generating properly. The metabolic interaction is where it gets genuinely interesting. GH is counter-regulatory: it induces insulin resistance in muscle and adipose, raises hepatic glucose output, and drives free fatty acids up, which further impairs insulin signalling. LR3 does the opposite, engaging IGF1R and insulin receptors to lower glucose. Run together, these do not cancel cleanly - they operate on different timescales, GH's insulin resistance building over hours to days while LR3's glucose drop happens within the hour. The practical consequence is a glucose profile that is harder to predict than either compound alone, which is why people who felt safe on LR3 alone get caught out on the stack. On the growth side, the combination genuinely does produce higher total IGF-1 receptor occupancy than either alone, and both fluid retention and both mitogenic profiles stack too.

The failure that recurs is starting both components in the same week. GH-induced insulin resistance takes days to establish and varies with dose, training and food; LR3's glucose drop is immediate. Start them together and you have no idea which compound is responsible for anything you observe, and no baseline against which to judge a low reading. Run GH alone for two weeks first. The second failure is the belief that GH's insulin resistance makes LR3 safe. It buffers the glucose drop unpredictably and by a variable amount, and people who correctly conclude they can tolerate more LR3 on the stack find out on the day the buffering is weaker. The third is dose creep on both sides simultaneously, which makes the stack uninterpretable and pushes total IGF-1 into acromegalic territory - and unlike LR3 alone, the GH component causes the structural changes if sustained: cardiac hypertrophy, jaw and hand growth, sleep apnoea. The fourth is running it for months without measuring IGF-1, which is the one number that tells you whether you are in physiological range or well past it. And the fifth, quietly, is that the whole rationale is unsound: GH already produces the local muscle IGF-1 signal that matters most for hypertrophy, so the added LR3 is largely redundant on the anabolic side while being fully additive on the risk side.

1. —Weeks 1-2 — GH alone at the intended dose, no LR3. Establish your glucose baseline on the GH-induced insulin resistance before adding a hypoglycaemic agent to it. Skipping this step is the single most common reason this stack goes wrong.
2. 20 mcgWeek 3 — Add LR3 at 20 mcg daily, injected with a carbohydrate-containing meal, with CGM running. Do not change the GH dose in the same week.
3. 30 mcgWeeks 4-5 — Only if week three produced no glucose readings under 70 mg/dL. One variable at a time, always.
4. 40 mcgWeeks 6-8 — Practical ceiling for the LR3 component on this stack, and lower than the ceiling for LR3 alone, because GH-induced insulin resistance is not a reliable buffer and its magnitude varies day to day.

• Growth hormone receptor (GHR) — Native ligand affinity for recombinant hGH

  JAK2-STAT5 signalling. Direct lipolysis in adipose tissue, hepatic IGF-1 and IGFBP-3 production, local IGF-1 expression in muscle, and induction of insulin resistance.

• IGF-1 receptor (IGF1R) — Engaged from both directions - by GH-induced endogenous IGF-1 and directly by LR3

  PI3K/Akt/mTORC1 translation initiation, FoxO suppression, MAPK proliferation. Total receptor occupancy is higher than with either component alone.

• Insulin receptor and hybrid receptors — Weak agonism from LR3, plus GH-induced post-receptor insulin resistance acting in the opposite direction

  The two effects operate on different timescales and do not neutralise each other predictably. This is the source of the unpredictable glucose profile.

• IGFBP-3 and acid-labile subunit — Raised by GH; evaded by LR3

  GH builds the reservoir that extends endogenous IGF-1's residence time, while LR3 is engineered to bypass it. The two halves of the stack are working against each other on this specific axis.

Glucose effects from the LR3 component within 20-30 minutes of each injection. GH-induced fluid retention, joint aches, carpal tunnel symptoms and morning stiffness at weeks two to four. IGF-1 measurably elevated within two to four weeks. Insulin resistance building over four to eight weeks and visible in HOMA-IR before it appears in fasting glucose. Any composition change requiring eight to twelve weeks minimum, on top of training and food that would produce much of it regardless. Structural GH effects - cardiac, skeletal, soft tissue - developing over many months of sustained supraphysiological exposure.

This record is itself a stack, so the useful content here is what people add on top and what that costs. Insulin is the addition that has killed people in this population, and it is the one most frequently recommended alongside it: you would be combining a compound that causes insulin resistance, a compound that causes hypoglycaemia, and a compound that causes profound hypoglycaemia, on three different timescales. There is no monitoring regime that makes that predictable. Anabolic steroids are the more common real-world addition and are mechanistically independent - androgen receptor signalling and satellite cell recruitment rather than translation initiation - so the anabolic argument is at least coherent, but androgens worsen insulin sensitivity too and the cardiovascular load compounds. Thyroid hormone is added to counteract GH's effect on thyroid conversion, and doing that without measuring free T4, free T3 and TSH first is guessing. The secretagogue-based version of the stack, substituting a GHRH analogue plus a GHRP for recombinant GH, is meaningfully safer: it preserves pulsatility and negative feedback, so it cannot produce the sustained supraphysiological GH levels that drive the acromegalic changes, and it costs less. It also cannot exceed what your pituitary can release, which is the trade.

Against IGF-1 LR3 alone, the stack adds GH's direct lipolysis, its local muscle IGF-1 induction and its raised IGFBP-3, and adds insulin resistance, fluid retention and considerably more cost. Against GH alone, it adds an IGF-1 signal the GH was already generating more physiologically, plus a hypoglycaemia risk the GH did not have. That asymmetry is the honest summary: GH alone is the better-characterised half of this protocol and the half with real clinical data behind it. Against the secretagogue version, recombinant GH gives you a dose you control and supraphysiological levels you can reach; the secretagogue version preserves pulsatility and feedback and is safer and cheaper, at the cost of a lower ceiling. Against tesamorelin, which is the licensed GH-axis drug in this class: tesamorelin has over 800 patients of phase 3 data showing a measurable visceral fat effect, and this stack has none of that at any level. Against bimagrumab, which produced 7.5 kg of fat loss and 1.7 kg of lean gain in a randomised trial, the comparison is simply that one of these has evidence and the other has a tradition.

$300–$900/month. Grey-market recombinant GH runs roughly 200-600 USD a month at 2-4 IU daily, and the LR3 component adds 60-180 USD. A CGM at 60-130 USD a month is not optional on this protocol - it is the cheapest component and the only one that will tell you when something is going wrong.

• ?No study has ever examined this combination in humans. Everything here is inference from the pharmacology of the individual components.
• ?The magnitude and time course of GH-induced insulin resistance offsetting LR3-induced hypoglycaemia is unquantified and almost certainly varies substantially between individuals and days.
• ?IGF-1 LR3 has no human pharmacokinetics, so its contribution to total IGF-1 receptor occupancy on this stack cannot be calculated.
• ?Whether standard IGF-1 assays detect LR3 is unknown, which means the total exposure figure you measure on this stack may be an underestimate by an unknown amount.
• ?Whether adding exogenous IGF-1 to GH produces any hypertrophy beyond GH alone has never been tested, and the mechanism suggests substantial redundancy.
• ?The long-term mitogenic risk of combined sustained GH and IGF-1 receptor stimulation is not quantifiable from the available data, though the direction of concern is clear from acromegaly epidemiology.
• ?GH dosing in the underlying protocols is expressed in international units with vial potency varying by product, so the actual milligram exposure in any given grey-market protocol is uncertain.

• IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys Tomas FM, Walton PE, Dunshea FR, Ballard FJ, Journal of Endocrinology, 1997 · PMID 9415072

  Quantifies how much more hypoglycaemically potent LR3 is than native IGF-1, which is the number that matters when you add it to a compound that is already destabilising glucose.

• Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats Ballard FJ, Knowles SE, Walton PE, Edson K, Owens PC, Mohler MA, Ferraiolo BL, Journal of Endocrinology, 1991 · PMID 2005410

  Establishes that binding proteins prolong IGF-1's plasma residence. GH raises IGFBP-3, LR3 evades it - the two halves of this stack are pulling in opposite directions on that axis.

• EGRIFTA SV (tesamorelin) for injection - FDA prescribing information Theratechnologies Inc., DailyMed, U.S. National Library of Medicine

  The best available quantification of what raising GH does in a controlled setting: IGF-1 up by 107-108 ng/mL, glucose intolerance in 5% versus 1% on placebo. Use those numbers as the yardstick for the GH half of this stack.

• INCRELEX (mecasermin) injection, solution - FDA prescribing information Ipsen Biopharmaceuticals, Inc., DailyMed, U.S. National Library of Medicine

  The reference point for what IGF-1 receptor agonism costs even under supervision: 42% hypoglycaemia, five severe episodes and four with seizures or loss of consciousness in a 71-patient trial. The label also documents that clearance is inversely proportional to IGFBP-3, which is the specific mechanism by which GH alters IGF-1 kinetics.